| Trofinetide and NNZ-2591 publications |
|
|
| Year |
Journal |
Authors |
Subject |
| 2019 |
Neurology® 2019;92:e1912-e1925 |
Glaze et al |
Double-blind, ramdomized, placebo-controlled study of trofinetide in pediatric Rett syndrome |
| 2017 |
Pediatric Neurology S0887-8994(17)30405-8 |
Glaze et al |
A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome |
| 2017 |
Genes, Brain and Behavior 10.1111/gbb.12373 |
Deacon et al |
Nrf2, A Novel Therapeutic Target in Fragile X Syndrome is Modulated by NNZ-2566 |
| 2017 |
European Journal of Pharmaceutical Sciences 2017.05.032 |
Oosterholt et al |
Population pharmacokinetics of NNZ-2566 in healthy subjects |
| 2015 |
Journal of Child Neurology 1-6 |
Neul et al |
Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the Clinical Global Impression Scale |
| 2015 |
Neuromolecular Medicine 17: 71-82 |
Deacon et al |
NNZ-2566, a novel analog of (1–3) IGF-1, as a potential therapeutic agent for Fragile X syndrome |
| 2013 |
NeuroMolecular Medicine 15 (3): 504-14 |
Cartagena et al |
Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3 |
| 2010 |
Behavioural Brain Research 210 (2010) 221-228 |
Guan et al |
NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat |
| 2009 |
British Journal of Pharmacology (2009) 156, 662-672 |
Krishnamurthi et al |
A novel diketopiperazine improves functional recovery given after the onset of 6-OHDA-induced motor deficit in rats |
| 2009 |
Journal of Neurotrauma 26: 141–154 |
Lu et al |
NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury |
| 2009 |
Journal of Cerebral Blood Flow & Metabolism 00: 1-9 |
Lu et al |
NNZ-2566, a glypromate analog, attenuates brain ischemia-induced nonconvulsive seizures in rats |
| 2009 |
Journal of Neuroinflammation 6: 19-29 |
Wei et al |
NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats |
| 2009 |
Journal of the Neurological Sciences 278 (1-2): 85-90 |
Bickerdike et al |
NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke |
| 2007 |
Developmental Neuroscience 29: 393-402 |
Svedin et al |
Delayed peripheral administration of a GPE analogue induces astrogliosis and angiogenesis and reduces inflammation and brain injury following hypoxia-ischemia in the neonatal rat |
| Other relevant publications |
|
|
| Year |
Journal |
Authors |
Subject |
| 2019 |
Molecular Psychiatry s41380-018-0325-9 |
Wang et al |
A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability |
| 2014 |
Acta Neuropathologica 128: 333-345 |
Derecki et al |
Microglia as a critical player in both developmental and late-life CNS pathologies |
| 2014 |
Scientific Reports 4 : 4388 |
Guan et al |
Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1 |
| 2013 |
Molecular Autism 4:9 |
Bozdagi et al |
IGF-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay |
| 2013 |
Glia 61: 24-36 |
Schafer et al |
The Quad-partite synapse: microglia-synapse interactions in the developing and mature CNS |
| 2013 |
Journal of Neuroinflammation 10:37 |
Suh et al |
IGF-1 and IGF-2 expression in human microglia differential regulation by inflammatory mediators |
| 2012 |
Neuroscience Letters 520: 51-56 |
Corvin et al |
IGF1 and its active peptide (1–3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms |
| 2012 |
Neuropsychopharmacology 37: 1152-1163 |
De Filippis et al |
Modulation of RhoGTPases Improves the Behavioral Phenotype and Reverses Astrocytic Deficits in a Mouse Model of Rett Syndrome |
| 2012 |
Nature 484 (7392): 105-109 |
Derecki et al |
Wild type microglia arrest pathology in a mouse model of Rett syndrome |
| 2011 |
Neuron Glia Biology 7 (01): 85-97 |
Maezawa et al |
Does microglial dysfunction play a role in autism and Rett syndrome |
| 2011 |
Nature 475 (7357): 497-500 |
Lioy et al |
A role for glia in the progression of Rett syndrome |
| 2011 |
Human Molecular Genetics 20: 1182-1196 |
Ricciardi et al |
Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model |
| 2010 |
Journal of Neuorscience 30 (15): 5346-5356 |
Maezawa et al |
Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate |
| 2010 |
Current Psychiatric Reports 12: 127-134 |
Gonzales et al |
The role of MeCP2 in brain development and neurodevelopmental disorders |
| 2009 |
PNAS 106: 2029-2034 |
Tropea et al |
Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice |
| 2009 |
British Journal of Pharmacology (2009), 157, 881–891 |
Guan et al |
IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions |
| 2007 |
Journal of Neuropathology and Experimental Neurology 66 (2): 117-123 |
Itoh et al |
Methyl CpG-Binding Protein 2 Directly Regulates Insulin-Like Growth Factor Binding Protein 3 in Mouse and Human Brains |
| 2004 |
Journal of Pediatric Neurology 2(3): 143-146 |
Guideri et al |
Echocardiographic evaluation in Rett children with cardiac dysautonomia |
| 2004 |
PNAS 101: 6033-6038 |
Luikenhuis et al |
Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice |
| 2003 |
Human Molecular Genetics 12 R221-R227 |
Kriaucionis et al |
DNA methylation and Rett syndrome |
| 2003 |
American Journal of Medical Genetics 122A: 227–233 |
Smeets et al |
Rett syndrome in adolescent and adult females: clinical and molecular genetic findings |
| 2002 |
Neuron 35: 243–254 |
Shahbazian et al |
Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3 |
| 2001 |
Brain Research 922: 42-50 |
Sizonenko et al |
Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic–ischemic injury |
| 2001 |
American Journal of Medical Genetics 104: 14-22 |
Zappella et al |
Preserved speech variants of the Rett syndrome molecular and clinical analysis |
| 1999 |
NeuroReport 10: 161-164 |
Saura et al |
Neuroprotective effects of Gly-Pro-Glu, the Nterminal tripeptide of IGF-1, in the hippocampus in vitro |
| 1999 |
Nature Genetics 23: 183 188 |
Amir et al |
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 |
| 1995 |
Neuron 14: 717-730 |
Beck et al |
IGF-1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatial parvalbumin-containing neurons |
| 1993 |
Annals New York Academy of Sciences 183-191 |
Sara et al |
The Biological Role of Truncated Insulin-like Growth Factor-1 and the Tripeptide GPE in the Central Nervous System |
| 1989 |
Biochemical and Biophysical Research Communications 165, 2, 766-771 |
Sara et al |
Identification of gly-pro-glu (gpe), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide |
